Compare SWKS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWKS | PTGX |
|---|---|---|
| Founded | 1962 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 8.5B |
| IPO Year | 1995 | 2016 |
| Metric | SWKS | PTGX |
|---|---|---|
| Price | $63.02 | $138.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $70.38 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 5.3M | 761.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.76 | 0.05 |
| Revenue | ★ $4,086,900,000.00 | N/A |
| Revenue This Year | N/A | $874.25 |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | ★ $78.66 | $2,685.40 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.93 | $50.49 |
| 52 Week High | $90.90 | $143.29 |
| Indicator | SWKS | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 63.37 |
| Support Level | $52.70 | $87.74 |
| Resistance Level | $63.01 | $141.10 |
| Average True Range (ATR) | 2.79 | 6.79 |
| MACD | 0.20 | -0.26 |
| Stochastic Oscillator | 55.44 | 80.75 |
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.